NEUROCRINE BIOSCIENCES INC Uncategorized Contracts & Agreements
67 Contracts & Agreements
- Neurocrine Biosciences, Inc. Inducement Plan, as amended (Filed With SEC on February 13, 2018)
- Amended and Restated Product Agreement dated June 27, 2017 by and between Patheon UK Limited and the Company (Filed With SEC on November 1, 2017)
- Form of Indemnity Agreement entered into with each of the Companys executive officers and directors (Filed With SEC on November 1, 2017)
- Neurocrine Biosciences, Inc. 12780 El Camino Real San Diego, CA 92130 (Filed With SEC on February 14, 2017)
- NEUROCRINE BIOSCIENCES, INC. INDUCEMENT PLAN ADOPTED: SEPTEMBER 15, 2014 AMENDED: OCTOBER 7, 2014 AMENDED: APRIL 29, 2015 (Filed With SEC on July 29, 2015)
- NEUROCRINE BIOSCIENCES, INC. INDUCEMENT PLAN ADOPTED: SEPTEMBER 15, 2014 AMENDED: OCTOBER 7, 2014 (Filed With SEC on November 4, 2014)
- FINANCIAL STATEMENTS (Filed With SEC on July 30, 2009)
- Target Indication (Filed With SEC on February 4, 2009)
- Current assets (Filed With SEC on August 1, 2008)
- Target Indication (Filed With SEC on February 11, 2008)
- Target Indication (Filed With SEC on February 11, 2008)
- Target Indication (Filed With SEC on February 11, 2008)
- Target Indication (Filed With SEC on February 11, 2008)
- Target Indication (Filed With SEC on February 11, 2008)
- Current assets (Filed With SEC on November 2, 2007)
- Current assets (Filed With SEC on November 2, 2007)
- Current assets (Filed With SEC on November 2, 2007)
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (Filed With SEC on October 26, 2007)
- Current assets (Filed With SEC on August 3, 2007)
- Current assets (Filed With SEC on August 3, 2007)
- Current assets (Filed With SEC on August 3, 2007)
- Current assets (Filed With SEC on August 3, 2007)
- Current assets (Filed With SEC on August 3, 2007)
- Current assets (Filed With SEC on August 3, 2007)
- Current assets (Filed With SEC on August 3, 2007)
- Target Indication (Filed With SEC on February 9, 2007)
- Current assets (Filed With SEC on November 9, 2006)
- Current assets (Filed With SEC on May 3, 2006)
- Current assets (Filed With SEC on May 3, 2006)
- Amended agreement with GlaxoSmithKline dated February 7, 2006 (Filed With SEC on February 13, 2006)
- Target Indication (Filed With SEC on February 7, 2006)
- Exhibit No (Filed With SEC on January 19, 2006)
- Exhibit No (Filed With SEC on January 19, 2006)
- Description of Exhibit (Filed With SEC on November 1, 2005)
- Description of Exhibit (Filed With SEC on October 24, 2005)
- EXHIBITS. The following exhibits are (Filed With SEC on July 27, 2005)
- Description of Exhibit (Filed With SEC on June 24, 2005)
- Description of Exhibit (Filed With SEC on June 24, 2005)
- Target Indication (Filed With SEC on February 16, 2005)
- Target Indication (Filed With SEC on February 16, 2005)
